Improve global health through early detection, diagnosis and management of diseases.

Next-generation sequencing (NGS) assay that assesses a person’s increased risk of developing the disease based on their genetic makeup.

Liquid biopsy test that is intended for early detection of Lung, Stomach, Colon, Pancreas, Prostate, Breast and Ovarian cancers.

Liquid biopsy test that analyses ctDNA, CTCs and/or exosomes in the course of cancer. Recurrences or disease progression can thus be detected as early as possible and therapy can be adjusted.

Next-generation sequencing (NGS) assay that enables in-house comprehensive genomic profiling of tumor samples.